BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Express Scripts
Cantor Fitzgerald
Harvard Business School

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,131,566

« Back to Dashboard

Summary for Patent: 6,131,566

Title: Metered dose inhaler for albuterol
Abstract:A metered dose inhaler having all or part of its internal surfaces coated with one or more fluorocarbon polymers, optimally a blend of one or more fluorocarbon polymers in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formation comprising albuterol or a physiologically acceptable salt thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.
Inventor(s): Ashurst; Ian Carl (Ware, GB), Herman; Craig Steven (Raleigh, NC), Li-Bovet; Li (Scotch Plains, NJ), Riebe; Michael Thomas (Raleigh, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC) Glaxo Group Limited (Greenford Middlesex, GB)
Application Number:08/831,268
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Device; Use; Composition;

No matches for this query

International Patent Family for Patent: 6,131,566

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)791► Subscribe
African Regional IP Organization (ARIPO)9701114► Subscribe
Austria219934► Subscribe
Austria373613► Subscribe
Australia5480996► Subscribe
Australia710382► Subscribe
Bulgaria102021► Subscribe
Bulgaria64075► Subscribe
Brazil9604976► Subscribe
Canada2217950► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: